Slashing headcount, Flagship-backed, Chris Austin-led Vesalius sharpens focus

Less than seven months after Flagship-backed Vesalius emerged from stealth mode, the biotech has laid off 43% of its staff, citing a need to sharpen its focus.

Vesalius Therapeutics has cut 29 positions among its 67 staffers as a consequence of its “decision to refine its strategy and streamline its organization around its most immediate priorities,” according to a company statement shared with BioCentury. A spokesperson did not respond to an inquiry about how its priorities are evolving...